Related Experiment Videos
Effects of recombinant human erythropoietin on anaemic W/Wv and Sl/Sld mice
1Fujigotemba Research Laboratories Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan.
Abstract:
The effects of recombinant human erythropoietin (rHuEPO) on anaemic W/Wv and Sl/Sld mice were investigated. rHuEPO was injected every day for a week in doses up to 86,000 iu/kg. Wv/+ and Sld+ mice, which have genetically a weak anaemia, received 17 or 86 iu/kg of rHuEPO and showed dose-dependent increases in haemoglobin, PCV, RBC and reticulocytes to the same extent as that in normal mice. W/Wv mice also showed increases in the haematological parameters in response to 8600 iu/kg of rHuEPO but the dose was much higher than that for normal mice. A reticulocyte increase in W/Wv mice appeared later than in normal mice and was not sustained for 2 weeks even though the rHuEPO treatment was continued. Sl/Sld mice, however, did not show any significant haematological effect from doses up to 86,000 iu/kg. In both W/Wv and Sl/Sld mice receiving 8600 and 86,000 iu/kg of rHuEPO, respectively, an increase in splenic or bone marrow CFU-E was observed regardless of the defect in their haemopoietic systems. The plasma erythropoietin (EPO) level in W/Wv and Sl/Sld mice was inversely correlated with the haemoglobin, indicating that EPO production was not influenced by the haemopoietic defect and was regulated by the hypoxic properties of the anaemia. These results indicate that a large dose of exogenous rHuEPO is effective for the anaemia in W/Wv mice caused by a stem cell defect but not for the anaemia in Sl/Sld mice caused by a defective microenvironment.
Insights
Recombinant human erythropoietin (rHuEPO) effectively treated anemia in W/Wv mice with stem cell defects. However, Sl/Sld mice with microenvironment defects showed no response to rHuEPO, even at high doses.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Anemia is a condition characterized by a deficiency in red blood cells or hemoglobin.
- Recombinant human erythropoietin (rHuEPO) is a therapeutic protein used to stimulate red blood cell production.
- Mouse models with genetic defects are crucial for understanding anemia pathogenesis and treatment.
Purpose of the Study:
- To investigate the efficacy of rHuEPO in treating anemia in W/Wv and Sl/Sld mouse models.
- To determine the dose-dependent response of different anemia types to exogenous rHuEPO.
- To elucidate the mechanisms underlying rHuEPO's effectiveness or lack thereof in distinct genetic anemia models.
Main Methods:
- Administration of varying doses of rHuEPO to W/Wv and Sl/Sld mice.
- Monitoring of hematological parameters including hemoglobin, PCV, RBC, and reticulocytes.
- Assessment of CFU-E levels in splenic and bone marrow.
- Measurement of plasma erythropoietin (EPO) levels.
Main Results:
- W/Wv and Sl/Sld mice with mild anemia showed dose-dependent increases in hematological parameters with low-dose rHuEPO.
- W/Wv mice required higher rHuEPO doses and showed a delayed, unsustained reticulocyte response.
- Sl/Sld mice did not respond significantly to high-dose rHuEPO, despite increased CFU-E.
- Plasma EPO levels correlated inversely with hemoglobin, indicating hypoxic regulation.
Conclusions:
- Exogenous rHuEPO is effective for W/Wv mouse anemia caused by stem cell defects, but requires higher doses.
- rHuEPO is ineffective for Sl/Sld mouse anemia, which stems from a defective microenvironment.
- Anemia type dictates the response to rHuEPO, highlighting the importance of the underlying defect (stem cell vs. microenvironment).